Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Closed 05-22 16:00:00 EDT

18.97

-0.87

-4.39%

盘后18.97

+0.000.00%

19:07 EDT

High20.16	Low18.94	Vol342.23K
Open19.99	D1 Closing19.84	Amplitude6.15%
Mkt Cap1.20B	Tradable Cap755.80M	Total Shares63.13M
T/O6.59M	T/O Rate0.86%	Tradable Shares39.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":18.97,"timestamp":1779480000000,"preClose":19.84,"halted":0,"volume":342232,"hourTrading":{"tag":"盘后","latestPrice":18.97,"preClose":18.97,"latestTime":"19:07 EDT","volume":7888,"amount":149637.55,"timestamp":1779491242467,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.043850806451612954,"floatShares":39841600,"shares":63133400,"eps":-8.823121,"marketStatus":"Closed","change":-0.87,"latestTime":"05-22 16:00:00 EDT","open":19.99,"high":20.16,"low":18.94,"amount":6586315.072832,"amplitude":0.061492,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.823121,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":19.84,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.98,"preClose":19.84,"latestTime":"09:29 EDT","volume":2123,"amount":42158.699594,"timestamp":1779456599999,"change":0.14,"changeRate":0.007056,"amplitude":0.022177},"postHourTrading":{"tag":"盘后","latestPrice":18.97,"preClose":18.97,"latestTime":"19:07 EDT","volume":7888,"amount":149637.55,"timestamp":1779491242467,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.479865,"impliedVol":1.1522,"impliedVolPercentile":0.7915},"requestUrl":"/m/hq/s/ZBIO/tweets","defaultTab":"tweets","newsList":[{"id":"1151355812","title":"Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1151355812","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151355812?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:23","pubTimestamp":1779189784,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.The company announced that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636085840","title":"Zenas BioPharma presents Phase 3 obexelimab IgG4-RD data at EULAR congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636085840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636085840?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:07","pubTimestamp":1779188827,"startTime":"0","endTime":"0","summary":"Zenas BioPharma will present Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress in London on June 4, 2026.The trial met its primary endpoint, showing a 56% reduction in flare risk versus placebo over 52 weeks .Obexelimab also delivered statistically significant improvements on key secondary measures, including time to first flare requiring rescue therapy, complete remission rate, and lower cumulative glucocorticoid rescue use.Safety data showed fewer grade 3 or higher adverse events versus placebo  with no new safety signals.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL5gxT3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","BK4585","ZBIO","BK4112","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","BK4588","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858454","title":"Zenas Biopharma Announces Upcoming Presentation of Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd) at Eular 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636858454?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:05","pubTimestamp":1779188700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUABFGYRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144972324","title":"Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1144972324","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144972324?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:39","pubTimestamp":1779154765,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636883853","title":"Zenas BioPharma CEO Leon O. Moulder Jr acquires 60,000 shares for $1.01 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636883853","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636883853?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:13","pubTimestamp":1779153187,"startTime":"0","endTime":"0","summary":"Zenas BioPharma CEO Leon O. Moulder Jr. reported an indirect purchase of 60,000 common shares at a weighted average price of $16.88.Indirect beneficial ownership tied to the reported holdings totaled 96,928 shares following the transaction.Separately disclosed positions included 1.79 million shares held indirectly, with 423,155 shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL99h4M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas BioPharma CEO Leon O. Moulder Jr acquires 60,000 shares for $1.01 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009895","title":"Zenas BioPharma grants 51,075 inducement RSUs to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009895?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135323,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted 51,075 restricted stock units to newly hired employees on May 15.The awards vest in four equal installments, with 25% scheduled to vest on May 15 in each year from 2027 through 2030.Vesting is contingent on continued service through each vesting date, under the company’s 2026 Inducement Plan and individual award agreements.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9LmLHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","ZBIO","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009833","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009833?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUAGKTZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009330","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009330","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009330?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  18, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297026/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636070152","title":"Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2636070152","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636070152?lang=en_us&edition=fundamental","pubTime":"2026-05-19 00:30","pubTimestamp":1779121834,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. This phase 3 study, titled “A Phase 3, Randomized, Double-blind,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-tough-ms-segment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-tough-ms-segment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2028103732.USD","LU2271345857.HKD","ZBIO","LU2023251221.USD","IE00BZ1G4Q59.USD","BK4127","LU1244550494.USD","BK4139","LU0053666078.USD","LU2089283258.USD","LU2133065610.SGD","LU1989772923.USD","LU0912757837.SGD","LU1162221912.USD","LU0971096721.USD","LU0390134368.USD","LU1732800096.USD","BK4585","LU2111349929.HKD","LU1720051108.HKD","BK4516","LU0234570918.USD","LU1074936037.SGD","LU1064131342.USD","LU2089284900.SGD","LU1244550221.USD","LU1548497426.USD","BK4581","LU0795875169.SGD","LU1244550577.SGD","LU0882574139.USD","LU1363072403.SGD","LU0106261372.USD","LU1720051017.SGD","LU2264538146.SGD","LU0528227936.USD","LU0320765646.SGD","LU1668664300.SGD","LU2487616109.SGD","LU0006306889.USD","LU1988902786.USD","IE00BKVL7J92.USD","LU0210528500.USD","LU1732799900.SGD","LU0106831901.USD","BK4504","LU0795875086.SGD","LU0314104364.USD","BK4534","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635957085","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635957085","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635957085?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:46","pubTimestamp":1778841960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 06:46 ET (10:46 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085586","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085586?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:40","pubTimestamp":1778841616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zenas BioPharma, Inc. (ZBIO), Monopar Therapeutics I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BLSG","LU0029874061.USD","XBI","BK4588","BLSX","BK4112","ZBIO","LU0128526141.USD","BK4581","MNPR","BK4139","BK4585","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706269","title":"How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706269","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635706269?lang=en_us&edition=fundamental","pubTime":"2026-05-15 13:47","pubTimestamp":1778824020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma recently dosed the first subject in a Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers in China, with early data expected by year-end 2026.\nThis first-in-human study underscores ZB021’s potential as a differentiated oral alternative to injectable IL-17 biologics for autoimmune and inflammatory diseases, supported by preclinical data showing anti-inflammatory activity and favorable ADME...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/how-zenas-biopharmas-first-in-human-oral-il-17-trial-could-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/how-zenas-biopharmas-first-in-human-oral-il-17-trial-could-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4211","ISBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742611","title":"Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742611?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:37","pubTimestamp":1778780220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:37 ET (17:37 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635486067","title":"Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635486067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635486067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:17","pubTimestamp":1778764664,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Zenas BioPharma, Inc. today and set a price target of $45.00. Nierengarten covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635271381","title":"Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2635271381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635271381?lang=en_us&edition=fundamental","pubTime":"2026-05-14 17:57","pubTimestamp":1778752636,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz added an “upside 30-day catalyst watch” on shares of Zenas BioPharma (ZBIO) while keeping a Buy rating on the name w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-30-day-catalyst-watch-on-zenas-biopharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-30-day-catalyst-watch-on-zenas-biopharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635478780","title":"Zenas Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635478780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635478780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:31","pubTimestamp":1778679086,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryZenas Biopharma Inc ZBIO.OQ reported a quarterly adjusted loss of $1.46 per share for the quarter ended March 31, l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786747","title":"Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786747?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670742,"startTime":"0","endTime":"0","summary":"Zenas Biopharma outlined plans for global marketing submissions for obexelimab in IgG4-related disease, with FDA BLA filing targeted for Q2 2026 and EMA MAA filing targeted for H2 2026.Phase 3 INDIGO trial in IgG4-RD met primary endpoint, cutting flare risk 56% versus placebo ; 73% of treated patients remained flare-free through week 52.Safety profile in INDIGO showed serious adverse events at 10% versus 19% for placebo; grade 3 infections ran 2% versus 4%.Multiple sclerosis program orelabrutinib advanced with Phase 3 trials initiated in PPMS in Q3 2025 and naSPMS in Q1 2026.Pipeline updates included Phase 2 SLE topline data for obexelimab expected in Q4 2026; early-stage assets ZB021, ZB022, ZB014 guided to initial clinical readouts from late 2026 into 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL91ZBd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785125","title":"Zenas BioPharma doses first subject in Phase 1 trial of oral IL-17 inhibitor ZB021","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785125?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669427,"startTime":"0","endTime":"0","summary":"Zenas Biopharma dosed first subject in a Phase 1 study of ZB021, an oral IL-17AA/AF inhibitor, marking start of human testing for program aimed at autoimmune and inflammatory diseases.Trial will assess safety, tolerability, pharmacokinetics in healthy volunteers, then support a proof-of-concept readout in plaque psoriasis.Single-ascending-dose and multiple-ascending-dose results are scheduled for release by year-end 2026, with psoriasis proof-of-concept data expected in 2027.Development plan targets a potential move from proof-of-concept into registration-directed trials, which could shorten timeline to a pivotal program if early data support the approach.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2qPtX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","SG9999014005.SGD","LU2095319765.USD","NDAQ","ZBIO","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635978513","title":"Zenas Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of Zb021, a Novel, Potentially Best-in-Class Oral Il-17Aa/Af Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2635978513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635978513?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA7N9WRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785572","title":"InnoCare Pharma starts Phase 1 trial of oral IL-17 inhibitor ICP-054 (ZB021)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785572","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785572?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:46","pubTimestamp":1778669181,"startTime":"0","endTime":"0","summary":"InnoCare Pharma reported first patient enrolled in Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054 , marking start of human testing.No results have been presented; study will assess safety, tolerability, pharmacokinetics in healthy volunteers to support later proof-of-concept work in autoimmune diseases.Program sits within October 2025 licensing deal granting Zenas BioPharma exclusive rights to develop, manufacture, commercialize ICP-054 outside Greater China and Southeast Asia, with Phase 1 work conducted in China in collaboration with Zenas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8ZppzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","ZBIO","BK0239","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":0.0497},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.2334},{"period":"6month","weight":-0.4458},{"period":"1year","weight":0.8135},{"period":"ytd","weight":-0.4536}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}